Meridian Bioscience Boosts FY19 Adj. EPS Outlook - Quick Facts

(RTTNews) - While reporting financial results for the third quarter, life science company Meridian Bioscience, Inc. (VIVO) on Tuesday raised its adjusted earnings guidance for the full year 2019, including the effects of the recently completed acquisition of GenePOC business.

For fiscal 2019, the company raised its adjusted earnings guidance to a range of $0.63 to $0.65 per share from the prior guidance range of $0.60 to $0.65 per share.

Further, the company expects consolidated revenues to be down about 6 percent, with Diagnostics segment revenues being down in the high-single-digits and Life Science segment revenues being up in the low-single-digits.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $0.56 per share on a revenue decline of 5.30 percent to $202.53 million for the year. Analysts' estimates typically exclude special items.